Articles tagged with Fatty Liver Disease
Two studies presented at The International Liver Congress highlight the increasing burden of non-alcoholic fatty liver disease (NAFLD) in people with HIV infection, leading to a risk of progressive liver disease. NAFLD prevalence is higher in HIV-infected individuals than the general population.
A new study has uncovered important differences in the biological pathways that lead to cancer for alcoholic fatty liver disease compared to non-alcoholic fatty liver disease. The findings could benefit the more than 3 million people diagnosed with fatty liver disease each year, potentially leading to new cancer prevention strategies.
Scientists found that platelets play a key role in the development of fatty liver disease and liver cancer. Blocking platelet function or attaching to specific molecular sites may help prevent the condition.
Researchers at UC San Diego identified unique bacterial features in the stool of people with nonalcoholic fatty liver disease and their twins, allowing for 92% accurate diagnosis of liver cirrhosis. The test also showed promise in detecting previously undiagnosed cases with 87% accuracy.
Researchers discovered a novel molecular pathway for PAI-1 inhibition that reversed diet-induced obesity and its related health problems in mice. The investigational drug TM5614 showed significantly improved fasting levels of blood sugar, insulin, and LDL cholesterol, as well as a reduction in fatty liver disease.
Researchers have identified six proteins associated with early-stage non-alcoholic fatty liver disease (NAFLD), a condition that can progress to end-stage liver cirrhosis. The discovery of protein PIGR as a candidate biomarker for liver damage tests offers a promising new diagnostic tool.
A team of researchers has identified biomarkers in the blood that can predict the accumulation of toxic fats in the liver, a sign of early fatty liver disease. The discovery has the potential to lead to a blood test to detect those at risk of advanced fatty liver disease and could represent a new approach in precision medicine.
Researchers discovered 27 new molecules with significant therapeutic potential for treating fatty liver disease and obesity by activating the PPAR-delta protein. These molecules are currently undergoing pharmaceutical evaluations and show promise in improving physical endurance and reducing waistlines.
Researchers found that a low-sugar diet resulted in significant improvement in nonalcoholic fatty liver disease (NAFLD) in adolescent boys. The study showed a 31% reduction in liver fat in the low-free sugar diet group compared to the typical diet group.
A randomized clinical study found that a diet low in free sugars significantly improved nonalcoholic fatty liver disease (NAFLD) in adolescent boys. The study showed a reduction in NAFLD from 25% to 17% in the intervention group, compared to a 20% reduction in the usual diet group.
Researchers have developed a new model to study the health effects of metabolic protein AMPK, revealing its potential as a treatment for nonalcoholic fatty liver disease and other diseases. By activating AMPK in mice with fatty liver disease, scientists found that it lowered liver fat and protected against weight gain and obesity.
Research suggests that PCSK9 inhibitors can protect against NAFLD by inducing degradation of hepatic HNF1a protein, insulin resistance, and other mechanisms. The use of PCSK9 inhibitors also ameliorates NAFLD independently of low-density lipoprotein cholesterol level reduction.
A new study by USC researchers reveals that a fatty diet can trigger changes in the immune system leading to non-alcoholic steatohepatitis (NASH), a serious form of non-alcoholic fatty liver disease. The study identified a novel type of reparative macrophage that counteracts inflammation, offering potential pathways for future therapies.
Researchers at CU Anschutz Medical Campus discover that infant gut microbes altered by maternal obesity increase the risk of obesity and non-alcoholic fatty liver disease later in life. The study suggests that altering the microbiome through probiotics or supplements may help reduce this risk.
Researchers at the University of Minnesota Medical School have made a groundbreaking discovery about how liver cell communication affects disease progression. By studying the dialogue between hepatocytes and macrophages, they found that a specific ketone body metabolite helps protect against tissue fibrosis in non-alcoholic fatty liver...
Researchers from George Washington University aim to understand the role of brain endoplasmic reticulum stress in the development of non-alcoholic fatty liver disease. The study, funded by $2.4 million from the National Institutes of Health, will examine the link between ER stress and transcription factor activation in NAFLD development.
Researchers found three genetic variations linked to increased liver fat, which could lead to new treatment options for non-alcoholic fatty liver disease (NAFLD). The study, led by Westmead Institute for Medical Research, identified the mechanisms behind hepatic steatosis, a major risk factor for NAFLD.
Researchers discovered that breastfeeding for over six months lowers the risk of non-alcoholic fatty liver disease (NAFLD) in mothers. Women who breastfed one or more children for longer periods had a lower risk compared to those who did not breastfeed or breastfed for under one month.
Researchers identified Sav1, a component of the Hippo pathway, as a key mutated gene in fatty liver-associated liver cancer. This discovery may lead to new liver cancer treatments targeting the Hippo pathway.
A new study found that a web-based intervention is an effective approach to manage lifestyle changes in patients with NAFLD, reducing weight, and improving dietary intake. The web-based program was compared to group counseling and showed similar effectiveness after two years.
A new six-year single-center study found a web-based program to be an effective approach to manage lifestyle changes in patients with NAFLD, comparable to group-based interventions. The web program reduced weight loss and improved liver health, suggesting counseling as a key therapeutic option until drugs are approved.
Patients with non-alcoholic fatty liver disease (NAFLD) who consume moderate amounts of alcohol have a 36% decreased risk of early death, while heavy drinking increases the risk by 45%. The study suggests that moderate drinking may be beneficial for these patients.
Two recent studies reveal that mitochondrial proteins are broken down more quickly in fatty liver cells, reducing their activity. Meanwhile, liver cells with fatty liver disease show signs of overworking, using triglycerides instead of glucose to make energy and increasing reactive oxygen byproducts, which can damage proteins.
Researchers identified caspase-2 as a critical driver of non-alcoholic steatohepatitis (NASH), a chronic and aggressive liver condition. The study found that an inhibitor of caspase-2 could provide an effective way to treat or prevent NASH, possibly even reversing early symptoms.
A new test predicts advanced fibrosis in NAFLD patients, accurately identifying 92% of those at risk. The tool uses the PRO-C3 biological marker and combines it with clinical information for highly accurate results.
Fatty liver disease is a complex condition that can lead to severe complications like type 2 diabetes and cardiovascular disease. A new review article proposes the use of new diagnostic and therapeutic approaches to enable specific risk prognosis and individualized treatment.
A TGen-led study has found a link between DNA methylation and non-alcoholic fatty liver disease (NAFLD) in obese patients. The research identified four genes that may represent potential targets for new therapeutics.
Nonalcoholic fatty liver disease (NAFLD) has a significant impact on the US healthcare system, with estimated annual costs of $32 billion. The prevalence of NAFLD mirrors the rising trend of obesity in the United States, affecting roughly 100 million Americans.
Researchers identified a compound called phenylacetic acid (PAA) produced by gut bacteria linked to the early onset of Non-Alcoholic Fatty Liver Disease (NAFLD). The study suggests PAA could be used as a biological marker in the clinic to identify patients at increased risk of disease.
Researchers identified plasma lipid species as signatures of healthy or unhealthy metabolic states, including fatty liver disease. They also pinpointed genetic regulators of lipid species and their physiological functions using systems genetics approaches.
Scientists at the University of Edinburgh have developed a lab-based system for studying Non-Alcoholic Fatty Liver Disease (NAFLD), the most common cause of liver disease in the developed world. The new tool enables researchers to investigate biological mechanisms and develop effective treatments.
A recent study found that UK children with non-alcoholic fatty liver disease have insufficient vitamin D levels throughout the year, particularly during winter months. Genetic variations in the vitamin D metabolic pathway are also associated with increased liver fat and inflammation.
Researchers identified two tryptophan metabolites produced by gut bacteria that modulate inflammation, potentially reducing the severity of non-alcoholic fatty liver disease. The study found that these metabolites reduce cytokine levels and macrophage activity, which are key contributors to inflammation.
Researchers at Bar-Ilan University have identified a family of indoline compounds with potent activity against pro-inflammatory cytokines and ROS toxicity. These novel substances show promise in treating acute pancreatic inflammation, fatty liver damage, and diabetes.
A new study has reported a good correlation between an automated image analysis system and an expert reviewer for the identification of key markers of NASH disease activity in a pre-clinical model. The study used deep-learning algorithms applied to open-source pathology software (QuPath1) to accurately identify cell histology patterns ...
A study analyzed outcomes and costs for German patients with NAFLD/NASH who developed compensated cirrhosis, finding significant increases in comorbidities, mortality, and healthcare costs. The study highlights the need for new treatment options to improve patient outcomes.
Patients with NAFLD achieved similar weight loss and normalized liver enzymes through a web-based lifestyle modification programme. The study suggested that the degree of weight loss was likely to have resulted in fibrosis regression.
A new study published in the Journal of Pediatrics found that children as young as 8 years old with obesity are at risk for nonalcoholic fatty liver disease. Elevated waist circumference at age 3 and increased weight gain between ages 3 and 8 are associated with higher levels of a liver enzyme called ALT.
Research found that women with PCOS are two to three times more likely to develop non-alcoholic fatty liver disease, regardless of their weight. High testosterone levels also increase the risk, even in normal-weight women.
A new study published in the Journal of Hepatology links high consumption of red and processed meat to non-alcoholic fatty liver disease and insulin resistance. High meat eaters had a higher risk of developing NAFLD and insulin resistance, regardless of saturated fat intake.
Empagliflozin, a treatment for type 2 diabetes, has been shown to reduce liver fat in patients with nonalcoholic fatty liver disease (NAFLD). The study found that patients receiving empagliflozin experienced a significant decrease in liver fat compared to those on standard treatment alone.
A new study suggests that e-cigarette use may lead to an accumulation of fat in the liver, potentially detrimental to health. Researchers found changes in 433 genes associated with fatty liver development and progression in mice exposed to e-cigarettes.
A phase II clinical trial showed that NGM282 significantly reduced liver fat content in patients with NAFLD and NASH. The treatment, a non-tumorigenic variant of an endocrine gastrointestinal hormone, has no FDA-approved treatments for these conditions.
Researchers discovered the role of adenosine 2A receptor in preventing NAFLD, showing disrupted receptors lead to increased inflammation and fat deposition. The study validates this receptor as a potential therapeutic target for treating non-alcoholic fatty liver disease.
A new scanning technology could almost halve the number of liver biopsies carried out on people with fatty liver disease. The study used digital image scanning to diagnose liver disease and found it to be superior to other tests in grading disease severity and excluding patients at increased risk.
Boston University researcher Michelle T. Long has received a five-year, $1 million NIH grant to continue her research on non-alcoholic fatty liver disease (NAFLD). Her study will focus on the clinical and genetic traits associated with hepatic fibrosis in 3,500 participants.
Researchers found PQQ can prevent fatty liver disease progression in young mice fed a high-fat diet by protecting their microbiome. The study suggests that maternal diet affects offspring's gut health, leading to an increased risk of developing the disease.
A new study found that both alcohol consumption and metabolic factors contribute to the risk of severe liver disease in the general population. The research, published in Hepatology, suggests that considering both factors together can improve risk assessment and detection of individuals at high risk of progressive liver disease.
Researchers are developing new diagnostic tests and imaging techniques to diagnose NAFLD severity, predict disease progression, and monitor changes. The €34 million LITMUS project brings together clinicians, scientists, and pharmaceutical companies to create more accurate blood tests and treatments.
A €34 million European research project aims to develop new diagnostic tests for non-alcoholic fatty liver disease (NAFLD) and identify those at risk of severe inflammation and liver scarring. The project, LITMUS, brings together clinicians, scientists, and pharmaceutical companies to develop and validate biomarkers for testing NAFLD.
A study published in the Journal of Hepatology found that nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of liver, colorectal, and breast cancers. Patients with NAFLD were 16.73 times more likely to develop hepatocellular carcinoma and twice as likely to develop colorectal cancer.
A recent study has identified Neuregulin 4 (Nrg4) as a key driver of nonalcoholic steatohepatitis (NASH) progression. Increasing levels of Nrg4 protected liver cells from metabolic stress in mice, while loss of the hormone led to accelerated disease progression.
A new study found that hospital admission for non-alcoholic fatty liver disease (NAFLD) significantly raises the risk of cardiovascular disease and death in individuals with type 2 diabetes. NAFLD was associated with a 62% increase in incident cardiovascular events and a 40% increased risk of cardiovascular death.
A study found that increased DPP4 production in the liver contributes to obesity, fatty liver disease and insulin resistance. Elevated DPP4 levels also promote less sensitivity to insulin, increasing the risk of non-alcoholic fatty liver disease.
A study led by Cedars-Sinai found that patients with lower Braden Scale scores have higher risks of nonambulation, prolonged hospital stays, and rehabilitation facility discharge after liver transplantation. Supervised exercise programs may improve physical functioning and quality of life for these patients.
A drug called URMC-099 reversed liver inflammation and scarring in mice with non-alcoholic fatty liver disease. The research suggests that the drug may help treat a growing health concern in the US, affecting over 64 million people.
A new study suggests that genetic predisposition to type 1 inflammation protects against NAFLD, but type 2 inflammation actually worsens the condition. Targeted treatments for metabolic syndrome may need reevaluation due to this unexpected finding.
Research suggests type 2 immunity protects against metabolic disease but worsens nonalcoholic fatty liver disease (NAFLD) through inflammation and scarring. Inflammation in the liver involves immune molecules like IL-13, TGF-beta, and IFN-gamma.
Researchers at the University of Birmingham have discovered that increased male hormones, particularly AKR1C3 enzyme activity in fat tissue, drive PCOS women's risk to develop diabetes and fatty liver disease. Abdominal fat tissue is a major source of high levels of male hormones in women with PCOS.
Family members of individuals with non-alcoholic fatty liver disease (NAFLD) and cirrhosis are at a significantly higher risk of developing advanced liver fibrosis. A clinical trial found that immediate relatives had 12 times higher prevalence of liver fibrosis than healthy controls, indicating the need for screenings in family members.